Rheumatoid Arthritis and Diabetes: Reducing Cardiovascular Risk
Abatacept treatment resulted in a greater reduction in CVD risk compared with TNF inhibitors in patients with RA.
Sarilumab and tocilizumab have shown no clinically relevant differences in safety and tolerability outcomes.
National and international pharmacovigilance registry data pertaining to the use of biologic agents in patients with juvenile idiopathic arthritis have been combined.
Vitamin D deficiency was common and associated with higher disease activity and risk for juvenile idiopathic arthritis-associated uveitis.